Interstitial Cystitis Market Research Report and Forecast up to 2025 Interstitial Cystitis Market - Global Industry Ana

Interstitial Cystitis Market - Global Industry
Analysis, Size, Share, Growth, Trends, and
Forecast 2017 - 2025
Interstitial cystitis (IC), also known as painful bladder syndrome, is a chronic bladder
issue often associated with bladder pressure and pain, with occasional pain in either
the lower abdomen, pelvic, or lower back. The patient could experience pain raging
from mild to severe. The pelvic nerve signal to the brain gets mixed up in an
individual suffering from interstitial cystitis. Consequently, an urgency to urinate,
often in a small volume, is observed. On an average, a person urinates seven times
a day; however, in severe cases of IC, urination may occur around 40-60 times a
day. IC is not an infection, but is often mistaken to be a bladder infection. Factors
contributing to interstitial cystitis are: a defect of the epithelium layer of the
bladder, leaking epithelium allows toxic agents in urine to irritate the bladder wall.
Other anticipated, but not clear, contributing factors include heredity, an
autoimmune reaction, infection or allergy. Various therapies and medication may
provide relief from the symptoms for IC; however, there is still no cure for this
disease.
View Report @ http://www.transparencymarketresearch.com/interstitial-
cystitis-market.html
Studies conducted on interstitial cystitis and associated data have shown that it is
thrice more prevalent in women than in men, and the risk increases with age. The
female-to-male ratio is estimated to be 10:1. It is estimated that around 1 to4
million men and 3 to8 million women suffer from IC. Rise in prevalence of IC
stimulates the research and development on the drug, as it is likely to provide an
appropriate environment for newer products to be profitable. The prevalence of IC is
estimated to be between 2.7% to 6.53% among older women in the United States.
Patients suffering from other conditions such as fibromyalgia, irritable bowel
syndrome, or allergies often experience IC. According to a publication by National
Institutes of Health (NIH), in 2012, the annual expenditure for medication for the
geriatric population aged ≥65 years who are Medicare beneficiaries was US$
249,160,233 (nonspecific and specific IC combined).
IC is mainly diagnosed by urine analysis, bladder ultrasound, cystoscopy, biopsy of
bladder and urethra, bladder stretching, and prostrate fluid culture. The main goal is
to relieve the symptoms of IC, and thus treatment is segmented into five phases:
First phase by Physical therapy, second phase treatment by oral medication such as
Amitriptyline – to regulate the bladder spasms, Pentosan (Elmiron) – helps rebuild
the tissue lining the bladder, hydroxyzine, use of steroids, and dimethyl sulfoxide to